Most men should stop PSA screening at age 70, and some should stop earlier. The U.S. Preventive Services Task Force gives a Grade D recommendation against PSA-based prostate cancer screening for men 70 and older, meaning the evidence shows the harms outweigh the benefits at that age. But age alone isn’t the whole picture. Your overall health and life expectancy play a major role in whether continued screening makes sense.
The Age 70 Cutoff
The USPSTF recommends against PSA screening for all men 70 and older, including Black men and men with a family history of prostate cancer. This isn’t because prostate cancer stops being a concern. It’s because the slow-growing nature of most prostate cancers means that finding one after 70 is more likely to lead to unnecessary treatment than to save your life.
The European Randomized Study of Screening for Prostate Cancer found no mortality benefit for men who started screening at 70 or older. Any small decreases in cancer deaths were offset by the harms of overdiagnosis, meaning finding cancers that would never have caused symptoms or death. Between ages 70 and 74, an estimated 83% of screen-detected prostate cancers are excess cases that wouldn’t have needed treatment. By ages 75 to 79, that figure climbs to nearly 97%.
Life Expectancy Matters More Than Age
The American Cancer Society frames the decision differently: men without symptoms who have less than a 10-year life expectancy should not be offered screening, regardless of age. A healthy 68-year-old with well-managed blood pressure and no major chronic conditions has a different risk profile than a 65-year-old with diabetes, heart failure, and kidney disease. The first man might reasonably continue screening. The second might not benefit from it at all.
The 2023 American Urological Association guidelines reinforce this approach. They recommend that doctors tailor the screening interval, or choose to stop screening entirely, based on patient preference, current PSA level, prostate cancer risk factors, life expectancy, and general health. Their earlier 2013 guidelines had discouraged screening for men over 70 or those with a life expectancy under 10 to 15 years, and the updated guidance keeps that principle while emphasizing shared decision-making.
Why Overdiagnosis Is the Core Risk
Prostate cancer is unusual among cancers. Many prostate tumors grow so slowly that a man will die of something else long before the cancer causes any problem. When screening finds one of these slow-growing tumors, it sets off a chain of biopsies, imaging, anxiety, and often treatment with real side effects, including urinary incontinence and sexual dysfunction, for a cancer that was never going to be dangerous.
If PSA testing were eliminated for men 70 and older, researchers estimate it would reduce overdiagnosed cases by 42%. Eliminating it for men 65 and older would reduce overdiagnosis by 68%, and for men 60 and older by 85%. These numbers illustrate how sharply the risk of a “false alarm” cancer rises with age.
When Stopping Might Not Apply
The guidelines leave some room for individual circumstances. A man in his early 70s who is in excellent health and has a rising PSA trend might reasonably discuss continued monitoring with his doctor. Research on high-grade (aggressive) prostate cancer in older men found that those with few other health problems still benefited from treatment. For men with low comorbidity scores, aggressive treatment of high-grade disease reduced cancer deaths by about 11% over 10 years compared to watchful waiting. But for men with three or more significant health conditions, the benefit shrank to under 3%, and the difference was no longer statistically meaningful.
This means the conversation isn’t just about whether to screen. It’s about what you’d do with the result. If you’re healthy enough that you’d pursue treatment for an aggressive cancer, there may still be a case for screening into your early 70s. If your health is such that treatment would carry more risk than the cancer itself, continuing to screen creates anxiety without a clear path forward.
How to Have the Conversation
If you’re approaching 70 or already past it, a few questions can help frame the discussion with your doctor:
- What is your current PSA level and trend? A very low PSA in your 60s may support stopping screening earlier, since it signals low future risk.
- How is your overall health? Conditions like heart disease, diabetes, or chronic lung disease reduce your likelihood of benefiting from prostate cancer detection.
- What would you do with an abnormal result? If you’d decline biopsy or treatment, the screening itself serves little purpose.
- Do you have risk factors? A strong family history or Black ancestry raises prostate cancer risk, but the USPSTF still recommends against screening after 70 even for these groups, because the overdiagnosis problem persists.
For most men, stopping PSA screening at 70 aligns with the best available evidence. For men in poor health or with multiple chronic conditions, stopping earlier, perhaps in the mid-60s, is reasonable. The rare exception is a man in his early 70s with excellent health, a rising PSA, and a willingness to pursue treatment if cancer is found.